Harrow (NASDAQ:HROW – Get Free Report) released its quarterly earnings data on Monday. The company reported $0.25 EPS for the quarter, beating analysts’ consensus estimates of $0.19 by $0.06, FiscalAI reports. The company had revenue of $99.30 million during the quarter, compared to the consensus estimate of $98.59 million. Harrow had a negative net margin of 13.51% and a negative return on equity of 38.00%.
Harrow Trading Up 2.2%
Shares of Harrow stock traded up $0.58 during mid-day trading on Monday, hitting $27.47. The stock had a trading volume of 1,162,138 shares, compared to its average volume of 691,479. The firm has a 50-day moving average of $31.63 and a two-hundred day moving average of $37.91. The firm has a market cap of $1.03 billion, a P/E ratio of -27.47 and a beta of 0.18. The company has a quick ratio of 2.08, a current ratio of 2.24 and a debt-to-equity ratio of 19.70. Harrow has a 12-month low of $25.76 and a 12-month high of $54.85.
Analyst Ratings Changes
HROW has been the subject of a number of analyst reports. Leerink Partners started coverage on Harrow in a research report on Wednesday, September 9th. They issued an “outperform” rating and a $45.00 price target for the company. Wall Street Zen upgraded Harrow from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. Zacks Research downgraded Harrow from a “hold” rating to a “strong sell” rating in a research note on Tuesday, November 3rd. Weiss Ratings reiterated a “sell (e+)” rating on shares of Harrow in a report on Friday, October 16th. Finally, BTIG Research reiterated a “buy” rating and set a $63.00 price target on shares of Harrow in a report on Wednesday, October 7th. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, Harrow currently has a consensus rating of “Moderate Buy” and a consensus target price of $66.17.
Read Our Latest Stock Analysis on HROW
Insider Activity at Harrow
In other news, insider Amir Shojaei sold 11,250 shares of Harrow stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $40.00, for a total transaction of $450,000.00. Following the sale, the insider owned 11,250 shares of the company’s stock, valued at approximately $450,000. The trade was a 50.00% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 12.80% of the company’s stock.
Harrow Company Profile
Harrow, Inc is an ophthalmic pharmaceutical company focused on developing, acquiring, and commercializing prescription therapies for eye care. The company’s portfolio addresses conditions and procedures involving the ocular surface, anterior segment, and retina, with products intended for use by ophthalmologists and other eye-care professionals.
Harrow’s commercial products include VEVYE, a cyclosporine ophthalmic solution for the treatment of dry eye disease, and IHEEZO, a chloroprocaine hydrochloride ophthalmic gel used for ocular surface anesthesia during ophthalmic procedures.
See Also
- Five stocks we like better than Harrow
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for Harrow Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harrow and related companies with MarketBeat.com's FREE daily email newsletter.
